181 related articles for article (PubMed ID: 23053260)
1. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.
Qiu MT; Ding XX; Hu JW; Tian HY; Yin R; Xu L
Cancer Chemother Pharmacol; 2012 Dec; 70(6):861-73. PubMed ID: 23053260
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
Dehua Z; Mingming C; Jisheng W
PLoS One; 2018; 13(3):e0193814. PubMed ID: 29561887
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.
Xie J; Yuan J; Lu L
Diagn Pathol; 2014 Nov; 9():214. PubMed ID: 25421173
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
8. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
10. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
[TBL] [Abstract][Full Text] [Related]
12. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
[TBL] [Abstract][Full Text] [Related]
13. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
[TBL] [Abstract][Full Text] [Related]
14. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
15. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Ferrigno D; Buccheri G;
Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
[TBL] [Abstract][Full Text] [Related]
16. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Gao G; Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Lung Cancer; 2009 Sep; 65(3):339-44. PubMed ID: 19144444
[TBL] [Abstract][Full Text] [Related]
19. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
[TBL] [Abstract][Full Text] [Related]
20. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
